X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-11-12 | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | SVP, Finance | S - Sale+OE | $104.97 | -10,000 | 14,219 | -41% | -$1,049,658 | |||||
| D | 2026-11-12 | ORKA | Oruka Therapeutics, Inc. | Ball Kristine M | Dir | S - Sale+OE | $104.93 | -18,000 | 0 | -100% | -$1,888,749 | |||||
2026-11-11 | PBYI | Puma Biotechnology, Inc. | Miller Michael Patrick | Dir | S - Sale | $8.10 | -15,000 | 66,000 | -19% | -$121,457 | ||||||
2026-11-11 | SEPN | Septerna, Inc. | Ezekowitz Alan | Dir | S - Sale | $48.09 | -81,820 | 35,600 | -70% | -$3,934,363 | ||||||
| D | 2026-11-11 | TNGX | Tango Therapeutics, Inc. | Crystal Adam | Pres, R, D | S - Sale+OE | $25.00 | -5,000 | 115,743 | -4% | -$125,000 | |||||
| M | 2026-11-11 | CRVS | Corvus Pharmaceuticals, Inc. | Arcara Jeffrey | Chief Business Officer | P - Purchase | $11.22 | +4,500 | 4,500 | New | +$50,475 | |||||
2026-11-10 | ZLAB | Zai Lab Ltd | Gaynor Richard | Dir | P - Purchase | $27.19 | +1,228 | 81,965 | +2% | +$33,389 | ||||||
2026-11-11 | MANE | Veradermics, Inc | Enright Patrick G | Dir | S - Sale | $150.38 | -500,000 | 1,803,474 | -22% | -$75,190,000 | ||||||
2026-11-11 | MANE | Veradermics, Inc | Longitude Capital Partners V, LLC | 10% | S - Sale | $150.38 | -500,000 | 1,803,474 | -22% | -$75,190,000 | ||||||
2026-11-13 | NTHI | Neonc Technologies Holdings, Inc. | Heshmatpour Amir F | CEO, Pres, 10% | P - Purchase | $5.02 | +30,000 | 7,873,140 | 0% | +$150,501 | ||||||
| M | 2026-11-11 | KRRO | Korro Bio, Inc. | Formela Jean Francois | Dir | S - Sale | $14.61 | -66,632 | 121,219 | -35% | -$973,609 | |||||
| D | 2026-11-11 | MIRM | Mirum Pharmaceuticals, Inc. | Brege Laura | Dir | S - Sale+OE | $94.21 | -14,167 | 15,703 | -47% | -$1,334,656 | |||||
| D | 2026-11-12 | JNJ | Johnson & Johnson | Forminard Elizabeth | EVP, GC | S - Sale+OE | $284.39 | -13,072 | 16,994 | -43% | -$3,717,546 | |||||
2026-11-13 | ANIP | Ani Pharmaceuticals Inc | Cook Meredith | SVP, GC, SEC. | S - Sale | $70.80 | -500 | 72,924 | -1% | -$35,400 | ||||||
| D | 2026-11-12 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $593.52 | -9,500 | 668,728 | -1% | -$5,638,445 | |||||
2026-11-11 | ALDX | Aldeyra Therapeutics, Inc. | Alfieri Michael | Principal Financial Officer | P - Purchase | $0.65 | +10,000 | 17,500 | +133% | +$6,500 | ||||||
| D | 2026-11-10 | CORT | Corcept Therapeutics Inc | Swisher Daniel N Jr | Dir | S - Sale+OE | $74.07 | -1,500 | 0 | -100% | -$111,105 | |||||
2026-11-13 | ALT | Altimmune, Inc. | Weaver Gregory L | CFO | P - Purchase | $1.62 | +10,000 | 73,005 | +16% | +$16,200 | ||||||
2026-11-13 | ALT | Altimmune, Inc. | Pisano Wayne | Dir | P - Purchase | $1.64 | +10,000 | 58,800 | +20% | +$16,350 | ||||||
2026-11-13 | ALT | Altimmune, Inc. | Durso Jerome Benedict | Pres, CEO | P - Purchase | $1.62 | +30,700 | 93,200 | +49% | +$49,694 | ||||||
2026-11-10 | IONS | Ionis Pharmaceuticals Inc | Hayden Michael R | Dir | P - Purchase | $29.64 | +5,000 | 81,298 | +7% | +$148,200 | ||||||
2026-11-11 | NXTC | Nextcure, Inc. | Adar1 Capital Management, LLC | 10% | P - Purchase | $5.10 | +12,333 | 750,289 | +2% | +$62,897 | ||||||
2026-11-03 | XBIT | Xbiotech Inc. | Simard John | Dir, 10% | P - Purchase | $2.05 | +70,000 | 4,261,690 | +2% | +$143,409 | ||||||
| M | 2026-11-12 | LPCN | Lipocine Inc. | Patel Mahesh V. | CEO | P - Purchase | $1.59 | +50,000 | 211,495 | +31% | +$79,488 | |||||
2026-11-13 | ABCL | Abcellera Biologics Inc. | Booth Andrew | CFO | P - Purchase | $11.33 | +8,600 | 622,359 | +1% | +$97,438 | ||||||
| M | 2026-11-11 | CATX | Perspective Therapeutics, Inc. | Puhlmann Markus | Chief Medical Officer | P - Purchase | $0.84 | +41,000 | 178,542 | +30% | +$34,545 | |||||
2026-11-12 | LRMR | Larimar Therapeutics, Inc. | Hamilton Thomas Edward | Dir | P - Purchase | $2.67 | +70,000 | 944,231 | +8% | +$187,082 | ||||||
| DM | 2026-11-10 | ROIV | Roivant Sciences Ltd. | Pulik Richard | CFO | S - Sale+OE | $41.58 | -300,000 | 222,046 | -57% | -$12,473,272 | |||||
2026-11-10 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale | $40.53 | -187,943 | 811,211 | -19% | -$7,617,074 | ||||||
| DM | 2026-11-10 | PVLA | Palvella Therapeutics, Inc. | Martini Jeffrey S | Chief Scientific Officer | S - Sale+OE | $166.65 | -12,500 | 0 | -100% | -$2,083,076 | |||||
2026-11-09 | RCKT | Rocket Pharmaceuticals, Inc. | Chaudhuri Sarbani | See Remarks | S - Sale | $2.33 | -4,872 | 257,937 | -2% | -$11,337 | ||||||
2026-11-10 | CYRX | Cryoport, Inc. | Sawicki Mark W | Chief Scientific Officer | S - Sale | $19.93 | -10,000 | 92,356 | -10% | -$199,261 | ||||||
| D | 2026-11-09 | CYRX | Cryoport, Inc. | Hancock Daniel M | Dir | S - Sale+OE | $20.21 | -74,379 | 69,052 | -52% | -$1,502,976 | |||||
2026-11-11 | XNCR | Xencor Inc | Cornelissen Bart Jan | SVP, CFO | S - Sale | $39.82 | -10,100 | 65,798 | -13% | -$402,182 | ||||||
| D | 2026-11-10 | XNCR | Xencor Inc | Ranieri Richard J | Dir | S - Sale+OE | $39.25 | -81,252 | 18,514 | -81% | -$3,189,435 | |||||
2026-11-11 | LRMR | Larimar Therapeutics, Inc. | Ben-Maimon Carole | Pres, CEO | P - Purchase | $2.77 | +18,050 | 542,104 | +3% | +$49,953 | ||||||
2026-11-11 | LRMR | Larimar Therapeutics, Inc. | Thomas Frank E | Dir | P - Purchase | $2.73 | +8,000 | 15,000 | +114% | +$21,800 | ||||||
2026-11-11 | LRMR | Larimar Therapeutics, Inc. | Truitt Joseph | Dir | P - Purchase | $2.80 | +3,500 | 6,250 | +127% | +$9,792 | ||||||
2026-11-11 | LRMR | Larimar Therapeutics, Inc. | Harlow John B. Jr. | Pres, COO | P - Purchase | $2.80 | +17,800 | 67,800 | +36% | +$49,918 | ||||||
2026-11-11 | LRMR | Larimar Therapeutics, Inc. | Celano Michael | CFO | P - Purchase | $2.71 | +18,460 | 234,245 | +9% | +$49,992 | ||||||
2026-11-11 | LRMR | Larimar Therapeutics, Inc. | Shankar Gopi | Chief Development Officer | P - Purchase | $2.71 | +5,000 | 81,443 | +7% | +$13,549 | ||||||
| DM | 2026-11-09 | DNTH | Dianthus Therapeutics, Inc. /De/ | Savitz Ryan | EVP, CFO, CBO | S - Sale+OE | $90.52 | -124,042 | 0 | -100% | -$11,228,720 | |||||
2026-11-10 | IRON | Disc Medicine, Inc. | Savage William Jacob | Chief Medical Officer | S - Sale | $85.09 | -16,035 | 63,445 | -20% | -$1,364,437 | ||||||
| D | 2026-11-09 | ABBV | Abbvie Inc. | Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | S - Sale+OE | $293.60 | -40,619 | 81,059 | -33% | -$11,925,738 | |||||
| D | 2026-11-11 | SDGR | Schrodinger, Inc. | Abel Robert Lorne | See Remarks | S - Sale+OE | $34.00 | -23,605 | 54,219 | -30% | -$802,570 | |||||
2026-11-10 | LGND | Ligand Pharmaceuticals Inc | Aryeh Jason | Dir | S - Sale | $320.05 | -3,000 | 113,476 | -3% | -$960,141 | ||||||
| D | 2026-11-10 | ETON | Eton Pharmaceuticals, Inc. | Erdogan-Trinkaus Ipek | Chief Commercial Officer | S - Sale+OE | $67.41 | -3,500 | 4,081 | -46% | -$235,937 | |||||
2026-11-09 | CYTK | Cytokinetics Inc | Parshall B Lynne | Dir | S - Sale | $54.73 | -5,000 | 5,784 | -46% | -$273,635 | ||||||
| D | 2026-11-11 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $593.99 | -9,500 | 668,728 | -1% | -$5,642,870 | |||||
| D | 2026-11-10 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $586.33 | -9,500 | 668,728 | -1% | -$5,570,085 | |||||
| D | 2026-11-09 | KNSA | Kiniksa Pharmaceuticals International, Plc | Megna Michael R | CHIEF ACCOUNTING OFFICER | S - Sale+OE | $98.54 | -11,280 | 12,697 | -47% | -$1,111,531 | |||||
2026-11-10 | LYEL | Lyell Immunopharma, Inc. | Lee Gary K. | Chief Scientific Officer | S - Sale | $15.93 | -129 | 16,091 | -1% | -$2,055 | ||||||
2026-11-10 | LYEL | Lyell Immunopharma, Inc. | Hill Stephen J. | COO | S - Sale | $15.93 | -88 | 16,728 | -1% | -$1,402 | ||||||
| DM | 2026-11-09 | TEVA | Teva Pharmaceutical Industries Ltd | Daniell Richard | EVP, Europe Commercial | S - Sale+OE | $42.86 | -45,003 | 55,755 | -45% | -$1,928,944 | |||||
2026-11-10 | LYEL | Lyell Immunopharma, Inc. | Seely Lynn | Pres, CEO | S - Sale | $15.93 | -545 | 63,354 | -1% | -$8,682 | ||||||
2026-11-10 | TEVA | Teva Pharmaceutical Industries Ltd | Francis Richard D | Pres, CEO | S - Sale | $42.24 | -250,000 | 927,529 | -21% | -$10,559,175 | ||||||
2026-11-10 | LYEL | Lyell Immunopharma, Inc. | Bulis Veronica Sanchez | VP, Corporate Controller | S - Sale | $15.93 | -416 | 14,383 | -3% | -$6,627 | ||||||
| D | 2026-11-12 | TEVA | Teva Pharmaceutical Industries Ltd | Sabag Mark | See "Remarks" | S - Sale+OE | $44.14 | -44,710 | 80,760 | -36% | -$1,973,544 | |||||
| D | 2026-11-09 | TEVA | Teva Pharmaceutical Industries Ltd | Weiss Amir | Chief Accounting Officer | S - Sale+OE | $43.04 | -17,289 | 3,537 | -83% | -$744,049 | |||||
2026-11-10 | ALNY | Alnylam Pharmaceuticals, Inc. | Sigal Charles Elliott | Dir | P - Purchase | $152.25 | +1,600 | 5,046 | +46% | +$243,600 | ||||||
2026-11-09 | ALNY | Alnylam Pharmaceuticals, Inc. | Schulman Amy W | Dir | P - Purchase | $156.82 | +1,910 | 25,959 | +8% | +$299,526 | ||||||
| DM | 2026-11-09 | AMLX | Amylyx Pharmaceuticals, Inc. | Frates James M | CFO | S - Sale+OE | $30.19 | -40,000 | 400,156 | -9% | -$1,207,742 | |||||
2026-11-09 | AMLX | Amylyx Pharmaceuticals, Inc. | Klee Justin B. | Co-CEO | S - Sale | $29.84 | -100,000 | 3,513,056 | -3% | -$2,983,838 | ||||||
2026-11-09 | AMLX | Amylyx Pharmaceuticals, Inc. | Cohen Joshua B | Co-CEO | S - Sale | $29.84 | -100,000 | 3,513,123 | -3% | -$2,983,678 | ||||||
2026-11-12 | ABCL | Abcellera Biologics Inc. | Thermopylae Holdings Ltd. | 10% | P - Purchase | $11.54 | +60,565 | 56,194,662 | 0% | +$698,920 | ||||||
2026-11-10 | AQST | Aquestive Therapeutics, Inc. | Daly Richard J | Dir | P - Purchase | $3.54 | +28,025 | 28,025 | New | +$99,331 | ||||||
| M | 2026-11-09 | AVLN | Avalyn Pharma Inc. | Fmr LLC | See Remark 1, 10% | S - Sale | $29.33 | -228,454 | 2,056,081 | -10% | -$6,701,004 | |||||
| M | 2026-11-10 | PHIO | Phio Pharmaceuticals Corp. | Deming David H | Dir | P - Purchase | $0.84 | +12,000 | 49,800 | +32% | +$10,066 | |||||
2026-11-11 | CATX | Perspective Therapeutics, Inc. | Spoor Johan M. | CEO | P - Purchase | $0.81 | +47,000 | 134,683 | +54% | +$37,943 | ||||||
2026-11-11 | TNXP | Tonix Pharmaceuticals Holding Corp. | Lederman Seth | CEO | P - Purchase | $4.06 | +5,000 | 36,007 | +16% | +$20,275 | ||||||
2026-11-10 | MBX | Mbx Biosciences, Inc. | Hoerter Steven L. | COB, Pres, CEO | S - Sale | $54.82 | -4,893 | 98,045 | -5% | -$268,234 | ||||||
| M | 2026-11-09 | NTHI | Neonc Technologies Holdings, Inc. | Chen Thomas C | CMO, 10% | P - Purchase | $3.99 | +5,016 | 4,690,602 | 0% | +$20,001 | |||||
| M | 2026-11-10 | NTHI | Neonc Technologies Holdings, Inc. | Heshmatpour Amir F | CEO, Pres, 10% | P - Purchase | $4.21 | +70,000 | 12,373,280 | +1% | +$294,500 | |||||
2026-11-09 | SPRO | Spero Therapeutics, Inc. | Rajavelu Esther | See Remarks | S - Sale | $1.04 | -40,851 | 946,000 | -4% | -$42,485 | ||||||
| D | 2026-11-10 | ETON | Eton Pharmaceuticals, Inc. | Casamento Charles J | Dir | S - Sale+OE | $66.35 | -80,555 | 0 | -100% | -$5,345,072 | |||||
| D | 2026-11-10 | EWTX | Edgewise Therapeutics, Inc. | Nofi Michael | CFO | S - Sale+OE | $45.43 | -4,442 | 6,495 | -41% | -$201,787 | |||||
| M | 2026-11-06 | BOLD | Boundless Bio, Inc. | Tang Kevin | 10% | P - Purchase | $2.40 | +1,949 | 3,035,567 | 0% | +$4,678 | |||||
| D | 2026-11-06 | ONC | Beone Medicines Ltd. | Ball Titus B. | Principal Accounting Officer | S - Sale+OE | $405.57 | -1,559 | 97,929 | -2% | -$632,277 | |||||
| D | 2026-11-06 | JAZZ | Jazz Pharmaceuticals Plc | Cozadd Bruce C | Dir | S - Sale+OE | $235.95 | -68,808 | 357,567 | -16% | -$16,235,517 | |||||
2026-11-09 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale | $584.59 | -1,614 | 668,728 | 0% | -$943,521 | ||||||
| D | 2026-11-09 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $572.69 | -7,886 | 670,342 | -1% | -$4,516,253 | |||||
| D | 2026-11-09 | UTHR | United Therapeutics Corp | Patusky Christopher | Dir | S - Sale+OE | $580.00 | -1,210 | 3,240 | -27% | -$701,800 | |||||
2026-11-06 | VRTX | Vertex Pharmaceuticals Inc / Ma | Kewalramani Reshma | CEO, Pres | S - Sale | $531.53 | -11,866 | 86,471 | -12% | -$6,307,135 | ||||||
| D | 2026-11-09 | SDGR | Schrodinger, Inc. | Tran Yvonne | EVP, CLO, CPO | S - Sale+OE | $32.85 | -32,000 | 52,683 | -38% | -$1,051,123 | |||||
2026-11-06 | QURE | Uniqure N.V. | Meek David D. | Dir | S - Sale | $21.25 | -9,080 | 30,667 | -23% | -$192,950 | ||||||
2026-11-09 | BOLT | Bolt Biotherapeutics, Inc. | Coastlands Capital LP | 10% | P - Purchase | $6.38 | +50,000 | 462,416 | +12% | +$319,000 | ||||||
2026-11-09 | PRTA | Prothena Corp Public Ltd Co | Scully William P | 10% | P - Purchase | $8.53 | +140,000 | 1,693,000 | +9% | +$1,194,158 | ||||||
2026-11-09 | PHIO | Phio Pharmaceuticals Corp. | Plott Ronald Todd | Dir | P - Purchase | $0.83 | +18,300 | 60,300 | +44% | +$15,189 | ||||||
2026-11-09 | PHIO | Phio Pharmaceuticals Corp. | Bitterman Robert J | COB, Pres, CEO | P - Purchase | $0.82 | +25,000 | 789,871 | +3% | +$20,500 | ||||||
2026-11-05 | MTRI | Inmed Pharmaceuticals Inc. | Adar1 Capital Management, LLC | 10% | P - Purchase | $13.10 | +2,640 | 98,297 | +3% | +$34,572 | ||||||
2026-11-09 | NTHI | Neonc Technologies Holdings, Inc. | Heshmatpour Amir F | CEO, Pres, 10% | P - Purchase | $3.86 | +10,000 | 7,783,140 | 0% | +$38,600 | ||||||
2026-11-09 | ARVN | Arvinas, Inc. | Loomis David K | VP, Chief Accounting Officer | S - Sale | $6.36 | -232 | 39,961 | -1% | -$1,475 | ||||||
| D | 2026-11-06 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $564.51 | -9,500 | 668,728 | -1% | -$5,362,824 | |||||
2026-11-05 | NATR | Natures Sunshine Products Inc | Prescott Group Capital Management, L.L.C. | 10% | P - Purchase | $9.77 | +291,666 | 2,236,152 | +15% | +$2,849,811 | ||||||
2026-11-05 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale | $400.82 | -1,115 | 296,829 | 0% | -$446,910 | ||||||
2026-11-05 | OCUL | Ocular Therapeutix, Inc | Saroj Namrata | Chief Business Officer | S - Sale | $6.55 | -35,370 | 220,522 | -14% | -$231,674 | ||||||
| M | 2026-11-05 | NXTC | Nextcure, Inc. | Adar1 Capital Management, LLC | 10% | P - Purchase | $5.10 | +4,686 | 737,956 | +1% | +$23,899 | |||||
2026-11-05 | RCKT | Rocket Pharmaceuticals, Inc. | Wilson Martin | GC | S - Sale | $2.39 | -53,389 | 545,100 | -9% | -$127,813 | ||||||
2026-11-06 | LXRX | Lexicon Pharmaceuticals, Inc. | Exton Michael | CEO | P - Purchase | $1.66 | +30,064 | 328,496 | +10% | +$49,999 | ||||||
| M | 2026-11-05 | NTHI | Neonc Technologies Holdings, Inc. | Heshmatpour Amir F | CEO, Pres, 10% | P - Purchase | $3.29 | +70,000 | 7,773,140 | +1% | +$230,510 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |